ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by 't Jong, G.W.
Right arrow Articles by Stricker, B.H.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by 't Jong, G.W.
Right arrow Articles by Stricker, B.H.C.
Eur Respir J 2004; 23:310-313
Copyright ©ERS Journals Ltd 2004


Unlicensed and off-label prescription of respiratory drugs to children

G.W. 't Jong1,2, I.A. Eland2, M.C.J.M. Sturkenboom2,3, J.N. van den Anker1,5,6 and B.H.C. Stricker2,4

1 Dept of Paediatrics, Sophia Children's Hospital, 2 Pharmacoepidemiology Unit, Depts of Epidemiology and Biostatistics and Internal Medicine, 3 Dept of Medical Informatics, Erasmus University Medical Centre, Rotterdam, and 4 Drug Safety Unit, Inspectorate for Health Care, The Hague, the Netherlands. 5 Division of Pediatric Clinical Pharmacology, Children's National Medical Center, and 6 Depts of Pediatrics and Pharmacology, The George Washington University, Washington DC, USA

CORRESPONDENCE: B.H.C. Stricker, Dept of Epidemiology & Biostatistics, Erasmus Medical Centre Rotterdam, PO Box 1738, 3000 DR, Rotterdam, the Netherlands. Fax: 31 104089382. E-mail: b.stricker@erasmusmc.nl

Keywords: children, drug use, epidemiology, off-label, respiratory, unlicensed

Received: February 11, 2003
Accepted September 26, 2003

This work was supported by the Sophia Foundation for Scientific Research through a research grant (SSWO project no. 293).

Many respiratory drugs are not available in formulations suitable for infants and toddlers. Efficacy and safety research is mostly restricted to older children. However, respiratory drugs are frequently used in children for common diseases like asthma, upper and lower respiratory tract infections, rhinitis and sinusitis. The unlicensed and off-label use of respiratory drugs in children were studied.

A population-based cohort study was conducted by using the computerised medical records in the Integrated Primary Care Information project. The study population comprised a random sample from all children aged 0–16 yrs who were registered with a general practitioner in 1998. All prescriptions for respiratory drugs during the study period were classified according to their licensing and off-label status.

The study population comprised 13,426 patients (51.7% male, median age 8.7 yrs), of whom 2,502 (19%) received 5,253 prescriptions for respiratory drugs in 1998. A total of 3,306 (62.9%) prescriptions concerned licensed drugs. Of the remaining 1,947 prescriptions (37.1%), 882 (16.8%) were unlicensed for use in children, and 1,065 (20.3%) were prescribed off-label. The 1-yr cumulative risk of receiving an unlicensed or off-label prescription was 45% among children with at least one prescription for a respiratory drug.

This population-based study showed that a large proportion of respiratory drugs prescribed by the general practitioner are unlicensed for use in children, or licensed but prescribed in an off-label manner. Results have to be interpreted with caution because they may unjustly suggest inaccurate prescribing, whereas it may be difficult to treat children with respiratory symptoms and diseases, because for many respiratory drugs paediatric data on safety and efficacy are insufficient. These findings underline the importance of research on suitable formulations, dosages and efficacy of respiratory drugs in children.




This article has been cited by other articles:


Home page
Eur J Public HealthHome page
G. Lusini, F. Lapi, B. Sara, A. Vannacci, A. Mugelli, J. Kragstrup, and L. Bjerrum
Antibiotic prescribing in paediatric populations: a comparison between Viareggio, Italy and Funen, Denmark
Eur J Public Health, April 5, 2009; (2009) ckp040v1.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
G. Permanand, E. Mossialos, and M. McKee
The EU's new paediatric medicines legislation: serving children's needs?
Arch. Dis. Child., September 1, 2007; 92(9): 808 - 811.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
A. F. Zuppa, P. C. Adamson, J. T. Mondick, L. A. Davis, D. A. Maka, M. Narayan, C. Nicholson, D. Patel, K. R. Collison, and J. S. Barrett
Drug Utilization in the Pediatric Intensive Care Unit: Monitoring Prescribing Trends and Establishing Prioritization of Pharmacotherapeutic Evaluation of Critically Ill Children
J. Clin. Pharmacol., November 1, 2005; 45(11): 1305 - 1312.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the European Respiratory Society.